Science Daily: Pharmacology News

JULY 10, 2025

Artificial intelligence is now designing custom proteins in seconds—a process that once took years—paving the way for cures to diseases like cancer and antibiotic-resistant infections. Australian scientists have joined this biomedical frontier by creating bacteria-killing proteins with AI.

Disease

Drugs.com

JUNE 9, 2025

MONDAY, June 9, 2025 — Prompt treatment with a drug combo can effectively manage chronic kidney disease in people with type 2 diabetes, a new clinical trial shows. Patients prescribed the combination of finerenone and empagliflozin.

Treatment

Science Daily: Pharmacology News

MARCH 24, 2025

The study is among the first to examine multiple dietary patterns in midlife in relation to overall healthy aging.

Disease

Drug Target Review

JUNE 9, 2025

The landscape of genetic medicine is undergoing a profound transformation, driven by innovative approaches that challenge the traditional, disease-specific paradigms. My transition to biotech and rare diseases was deeply personal – my son was diagnosed with Duchenne muscular dystrophy in 2020. “My

Disease

Science Daily: Pharmacology News

JUNE 19, 2025

This one-shot strategy could revolutionize how we fight not just HIV, but many infectious diseases. By combining two immune-boosting adjuvants alum and SMNP the vaccine lingers in lymph nodes for nearly a month, encouraging the body to produce a vast array of antibodies. And best of all, it's built on components already known to medicine.

Vaccine

Science Daily: Pharmacology News

JULY 5, 2025

Scientists at the University of Sydney have uncovered a malfunctioning version of the SOD1 protein that clumps inside brain cells and fuels Parkinson’s disease.

Therapies

Science Daily: Pharmacology News

JULY 12, 2025

This breakthrough holds major promise for studying neurological diseases like Alzheimer’s and Parkinson’s, creating more accurate models for drug testing, and eventually even enabling neuron replacement therapies.

Research

BioPharma Drive: Drug Pricing

JUNE 2, 2025

Genetic research is driving progress in kidney disease drug discovery.

Disease

Science Daily: Pharmacology News

JULY 18, 2025

The findings hint at vast possibilities in treating diseases influenced by vitamin D, though long-term impacts remain uncertain. This opens the door to highly targeted cancer therapies—by either cutting off vitamin D supply to tumors or enhancing the gene’s activity to boost health.

Therapies

Broad Institute

MAY 21, 2025

Scientists create next generation of tools in battle against brain disease By Corie Lok May 21, 2025 Breadcrumb Home Scientists create next generation of tools in battle against brain disease The findings contained in eight studies could lead to targeted gene therapies for brain disorders. The tools are known as enhancer AAV vectors.

Disease

Science Daily: Pharmacology News

JANUARY 22, 2025

The breakthrough science focused on replicating heart tissues, bringing research closer to generating functional, bioprinted organs, which would have broad applications in disease modelling, drug screening and regenerative medicine.

Research

Science Daily: Pharmacology News

JUNE 26, 2025

With its cutting-edge design, it might just revolutionize how and where we detect disease, pollutants, and more. This self-illuminating sensor uses a gold nanostructure to both generate and sense light, making it incredibly compact, ultra-sensitive, and perfect for rapid diagnostics or environmental testing.

Disease

BioPharma Drive: Drug Pricing

JULY 10, 2025

The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.

Treatment

BioPharma Drive: Drug Pricing

JUNE 2, 2025

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a competitive corner of drug research, later this year.

Disease

Science Daily: Pharmacology News

JULY 6, 2025

Those with high-risk genes even saw cognitive gains, hinting at real disease-modifying power. Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over 12 months, whereas placebo patients worsened.

Disease

Chemical Biology and Drug Design

NOVEMBER 4, 2024

Alzheimer's disease (AD) is a progressive age-related neurodegenerative brain disorder that destroys memory and other important mental functions. ABSTRACT Alzheimer's disease (AD) is a progressive chronic age-related neurodegenerative brain disorder characterized by the loss of memory and other cognitive functions.

Disease

BioPharma Drive: Drug Pricing

JUNE 5, 2025

A deal worth up to $712 million with the China-based biotech gives Cullinan T cell engagers aimed at BCMA and CD19, two targets of interest in inflammatory conditions.

Disease

Science Daily: Pharmacology News

MAY 7, 2025

Older adults who maintain curiosity and want to learn new things relevant to their interests may be able to offset or even prevent Alzheimer's disease. Psychologists shows one type of curiosity can increase well into old age, contradicting prior research.

Disease

Covalent Modifiers

DECEMBER 28, 2024

Ai-Lin Chen, Zih-Jheng Lin, Hsiao-Yu Chang, and Tsung-Shing Andrew Wang Journal of the American Chemical Society , 2025 [link] Reactive carbonyl species (RCS) are important biomarkers of oxidative stress-related diseases because of their highly reactive electrophilic nature.

Disease

Science Daily: Pharmacology News

FEBRUARY 17, 2025

The findings demonstrate the potential of this technology to pave the way for future treatments for a wide range of conditions such as Alzheimer's disease, amyotrophic lateral sclerosis, brain cancer, and drug addiction.

RNA

Drug Target Review

JUNE 16, 2025

Targeting GPCRs to fight inflammatory diseases GPCR-targeting drugs are well known therapies for a range of disease types, including cardio-metabolic, central nervous system and endocrinological disorders. It also holds potential for neuroinflammatory conditions such as certain types of migraine.

Disease

Broad Institute

NOVEMBER 4, 2024

By Lucy Mutz November 4, 2024 Credit: Juliana Sohn Kasper Lage is managing director of the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease. The overall goal is to translate genetic findings into biological mechanisms underlying disease that could be targeted with new medicines.

Disease

Covalent Modifiers

JUNE 25, 2025

2025 , 147 , 25 , 21512–21525 [link] Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy for treating various diseases. Xiaoqiang He, Shihan Zeng, Yalei Wen, Tao Yang, Chaoming Huang, Yifang Li, Zhang Zhang, Ke Ding, Tongzheng Liu, Yi Tan, and Zhengqiu Li J.

Targeted Protein Degradation

Drug Target Review

DECEMBER 20, 2024

Their work focuses on creating ‘digital twin generators’ – AI-driven models that predict how a patients disease may progress over time. AI-powered digital twins A key component of Unlearns work is its focus on digital twin technology, which uses AI to create personalised models of disease progression for individual patients.

Clinical Trials

Covalent Modifiers

FEBRUARY 10, 2025

The interaction of 14-3-3 with Tau, characterized by different phospho-site driven binding modes, forms a valuable, disease-relevant, 14-3-3 multivalent model PPI to explore this selectivity issue.

Biophysical Assays

Science Daily: Pharmacology News

MAY 29, 2025

Long considered a disease brought to the Americas by European colonizers, leprosy may actually have a much older history on the American continent.

Disease

Drug Target Review

JULY 1, 2025

Placebo arms, in particular, create ethical and logistical hurdles, especially in areas like rare disease and oncology. They are patient-specific outcome predictions, generated using disease-specific machine-learning models trained on large, longitudinal clinical datasets. Digital twins offer a way forward.

Clinical Trials

Drugs.com

JULY 24, 2025

THURSDAY, July 24, 2025 — Insulin delivered by nasal spray might be a potential treatment for Alzheimer’s disease, a new study says. An insulin nasal spray effectively reached key memory regions in the brains of a small group of older.

Treatment

Drugs.com

JUNE 18, 2025

The deal gives Lilly a potential new treatment for heart disease, The Wall Street Journal reported. WEDNESDAY, June 18, 2025 — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront.

Therapies

The Pharma Data

JUNE 12, 2025

The results come from a open-label, proof-of-concept, Phase 2 study (NCT04520451) and highlight rilzabrutinib’s potential as a disease-changing treatment option for a condition that currently has limited and non-specific treatment options and involves substantial patient suffering due to its chronic and progressive course.

Disease

Drug Target Review

OCTOBER 30, 2024

Imagine being able to create an in vitro replica of a diseased organ to study the molecular mechanism underlying the illness. Now take a step further: envision testing drugs in these organoids to identify the ones that can treat disease safely and effectively without needing to run expensive clinical trials first.

Treatment

Broad Institute

JULY 24, 2025

Related news Imaging combined with genetic screening of cells enhances genomic discoveries Although outbreaks of Ebola virus are rare, the disease is severe and often fatal, with few treatment options. The study’s approach could also be used to examine other pathogens and emerging infectious diseases and look for new ways to treat them.

Virus

Covalent Modifiers

JULY 9, 2025

link] Targeted protein degradation (TPD) is an emerging therapeutic approach for the selective elimination of disease-related proteins. Nathanael Schiander Gray , Zhe Zhuang , Woong Sub Byun , Zuzanna Kozicka , Katherine Donovan , Brendan Dwyer , Abby Thornhill , Hannah Jones , Zixuan Jiang , Xijun Zhu , Eric Fischer , Nicolas Thomä , Angew.

Targeted Protein Degradation

FDA Law Blog: Drug Discovery

NOVEMBER 10, 2024

Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.

Clinical Development

The Open Targets Blog

JUNE 18, 2025

integrated their GWAS findings with functional genomics data from relevant tissues, identifying 700 genes with high confidence of being involved in osteoarthritis, and eight biological processes key to the disease development, including circadian clock and glial cell functions. GWAS credible sets from Hatzikotoulas et al. GCST90566795 ).

Pharmacogenetics

Drug Target Review

MARCH 3, 2025

The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. “For diseases like Parkinson’s, it’s more than sufficient,” he explains.

Disease

Broad Institute

JUNE 11, 2025

First launched in 2015 and renewed in 2020, the program began as a recognition that while a majority of cardiovascular disease can be associated with lifestyle factors such as tobacco consumption, diet, and level of physical activity, genomics can influence an individual’s predisposition to cardiovascular disease, age of onset, and severity.

Disease